Kfh - Antioch
- Type
- Teaching hospital
- Where
- Antioch, CA
- Medicare CCN
- 050760
- Received
- $3,665,554 in 215 records, 2023 ($194 general, $3,665,360 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2023 | General payment | 1 | $194 |
| 2023 | Research payment | 214 | $3,665,360 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| PFIZER INC. | 151 | $2,010,395 | 2023 |
| Genentech, Inc. | 63 | $1,654,965 | 2023 |
| Cochlear Americas | 1 | $194 | 2023 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 214 | $3,665,360 |
| Long term medical supply or device loan | 1 | $194 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2023-12-27 | PFIZER INC. | $2,400 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2023 |
| 2023-12-26 | PFIZER INC. | $15,514 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-12-23 | PFIZER INC. | $750 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2023 |
| 2023-12-22 | PFIZER INC. | $26,091 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-12-21 | PFIZER INC. | $4,677 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-12-21 | Genentech, Inc. | $4,342 | Research payment | Cash or cash equivalent | Gazyva Biological, BioOncology | Gazyva for the treatment of MN | 2023 |
| 2023-12-20 | PFIZER INC. | $5,000 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-12-12 | PFIZER INC. | $1,200 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2023 |
| 2023-12-08 | PFIZER INC. | $750 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY O | 2023 |
| 2023-12-07 | PFIZER INC. | $27,684 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-12-06 | PFIZER INC. | $3,600 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2023 |
| 2023-12-06 | PFIZER INC. | $1,343 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-11-25 | PFIZER INC. | $31,442 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-11-24 | PFIZER INC. | $4,677 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-11-21 | PFIZER INC. | $2,500 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2023 |
| 2023-11-15 | Cochlear Americas | $194 | Long term medical supply or device loan | In-kind items and services | COCHLEAR NUCLEUS CI632 COCHLEAR IMPLANT WITH SLIM MODIOLAR ELECTRODE Device, Implantable hearing solution | 2023 | |
| 2023-11-14 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2023 |
| 2023-11-13 | Genentech, Inc. | $582 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | Chemo trastuzumab vs chemo trastuzumab pertuzumab | 2023 |
| 2023-11-09 | PFIZER INC. | $1,500 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT | 2023 |
| 2023-11-04 | PFIZER INC. | $10,161 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-11-04 | PFIZER INC. | $2,500 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY O | 2023 |
| 2023-10-30 | Genentech, Inc. | $5,564 | Research payment | Cash or cash equivalent | A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC | 2023 | |
| 2023-10-30 | Genentech, Inc. | $524 | Research payment | Cash or cash equivalent | A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC | 2023 | |
| 2023-10-27 | Genentech, Inc. | $5,356 | Research payment | Cash or cash equivalent | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | 2023 | |
| 2023-10-26 | PFIZER INC. | $6,000 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2023 |
| 2023-10-26 | Genentech, Inc. | $1,073 | Research payment | Cash or cash equivalent | CellCept Drug, Virology & Specialty Care | Randomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN | 2023 |
| 2023-10-24 | PFIZER INC. | $21,343 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-10-21 | PFIZER INC. | $4,887 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2023 |
| 2023-10-21 | PFIZER INC. | $1,243 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-10-17 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-10-13 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-10-11 | PFIZER INC. | $18,729 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-10-11 | PFIZER INC. | $2,446 | Research payment | Cash or cash equivalent | LITFULO Drug, IMMUNOLOGY | A PHASE 3 OPENLABEL MULTICENTER LONGTERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF06651600 IN ADULT AND ADOLESCE | 2023 |
| 2023-10-10 | PFIZER INC. | $2,486 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-10-04 | PFIZER INC. | $7,000 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2023 |
| 2023-10-04 | PFIZER INC. | $7,000 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2023 |
| 2023-10-04 | PFIZER INC. | $6,661 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2023 |
| 2023-09-28 | PFIZER INC. | $329,968 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | CLINICAL CHARACTERISTICS TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH HRHER2 BREAST CANCER IN THE UNITED STATES | 2023 |
| 2023-09-28 | Genentech, Inc. | $1,087 | Research payment | Cash or cash equivalent | Gazyva Biological, BioOncology | Gazyva for the treatment of MN | 2023 |
| 2023-09-23 | PFIZER INC. | $35,507 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-09-22 | Genentech, Inc. | $8,252 | Research payment | Cash or cash equivalent | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | 2023 | |
| 2023-09-22 | PFIZER INC. | $1,717 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-09-22 | PFIZER INC. | $1,500 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT | 2023 |
| 2023-09-22 | PFIZER INC. | $1,200 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT | 2023 |
| 2023-09-20 | PFIZER INC. | $14,420 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2023 |
| 2023-09-14 | PFIZER INC. | $71,985 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2023 |
| 2023-09-06 | PFIZER INC. | $6,796 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT | 2023 |
| 2023-09-02 | PFIZER INC. | $9,047 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-09-01 | PFIZER INC. | $2,627 | Research payment | Cash or cash equivalent | LITFULO Drug, IMMUNOLOGY | A PHASE 3 OPENLABEL MULTICENTER LONGTERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF06651600 IN ADULT AND ADOLESCE | 2023 |
| 2023-08-31 | PFIZER INC. | $2,381 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY O | 2023 |
| 2023-08-30 | PFIZER INC. | $8,400 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2023 |
| 2023-08-30 | PFIZER INC. | $378 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2023 |
| 2023-08-28 | Genentech, Inc. | $20,200 | Research payment | Cash or cash equivalent | A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC | 2023 | |
| 2023-08-26 | PFIZER INC. | $19,350 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT | 2023 |
| 2023-08-24 | PFIZER INC. | $30,932 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-08-24 | PFIZER INC. | $350 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2023 |
| 2023-08-23 | PFIZER INC. | $1,717 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-08-23 | Genentech, Inc. | $195 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2023 | |
| 2023-08-10 | PFIZER INC. | $3,050 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT | 2023 |
| 2023-08-09 | Genentech, Inc. | $12,108 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2023 | |
| 2023-08-08 | PFIZER INC. | $30,674 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2023 |
| 2023-08-08 | PFIZER INC. | $10,130 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-08-08 | PFIZER INC. | $757 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2023 |
| 2023-08-08 | PFIZER INC. | $378 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2023 |
| 2023-08-08 | PFIZER INC. | $189 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-08-05 | PFIZER INC. | $1,500 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY O | 2023 |
| 2023-08-01 | Genentech, Inc. | $850 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2023 | |
| 2023-07-28 | Genentech, Inc. | $15,258 | Research payment | Cash or cash equivalent | Gazyva Biological, BioOncology | Gazyva for the treatment of MN | 2023 |
| 2023-07-28 | PFIZER INC. | $7,728 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2023 |
| 2023-07-28 | Genentech, Inc. | $4,525 | Research payment | Cash or cash equivalent | Gazyva Biological, BioOncology | Gazyva for the treatment of MN | 2023 |
| 2023-07-28 | PFIZER INC. | $1,015 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2023 |
| 2023-07-26 | PFIZER INC. | $14,430 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-07-26 | PFIZER INC. | $2,400 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT | 2023 |
| 2023-07-25 | PFIZER INC. | $8,243 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-07-25 | Genentech, Inc. | $5,243 | Research payment | Cash or cash equivalent | A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC | 2023 | |
| 2023-07-20 | PFIZER INC. | $5,100 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2023 |
| 2023-07-20 | PFIZER INC. | $2,328 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2023 |
| 2023-07-19 | PFIZER INC. | $34,632 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2023 |
| 2023-07-19 | Genentech, Inc. | $5,085 | Research payment | Cash or cash equivalent | CellCept Drug, Virology & Specialty Care | Randomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN | 2023 |
| 2023-07-19 | PFIZER INC. | $1,200 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2023 |
| 2023-07-15 | PFIZER INC. | $26,785 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY O | 2023 |
| 2023-07-15 | PFIZER INC. | $600 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VA | 2023 |
| 2023-07-14 | Genentech, Inc. | $32,500 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2023 | |
| 2023-07-14 | Genentech, Inc. | $13,294 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2023 | |
| 2023-07-14 | Genentech, Inc. | $4,200 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2023 | |
| 2023-07-14 | Genentech, Inc. | $2,400 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2023 | |
| 2023-07-14 | Genentech, Inc. | $2,100 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2023 | |
| 2023-07-13 | PFIZER INC. | $8,100 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2023 |
| 2023-07-13 | PFIZER INC. | $3,750 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2023 |
| 2023-07-12 | PFIZER INC. | $5,792 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2023 |
| 2023-07-11 | Genentech, Inc. | $143,917 | Research payment | Cash or cash equivalent | 2023 | ||
| 2023-07-11 | PFIZER INC. | $22,457 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-07-10 | Genentech, Inc. | $15,610 | Research payment | Cash or cash equivalent | A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC | 2023 | |
| 2023-07-10 | Genentech, Inc. | $12,705 | Research payment | Cash or cash equivalent | A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC | 2023 | |
| 2023-07-06 | Genentech, Inc. | $80,000 | Research payment | Cash or cash equivalent | 2023 | ||
| 2023-07-04 | PFIZER INC. | $4,924 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2023 |
| 2023-07-04 | PFIZER INC. | $1,500 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-06-30 | PFIZER INC. | $757 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2023 |
| 2023-06-30 | PFIZER INC. | $757 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2023 |
| 2023-06-28 | PFIZER INC. | $2,148 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-06-27 | Genentech, Inc. | $1,143 | Research payment | Cash or cash equivalent | 2023 | ||
| 2023-06-24 | PFIZER INC. | $20,709 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-06-24 | PFIZER INC. | $9,028 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2023 |
| 2023-06-23 | PFIZER INC. | $12,000 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-06-22 | Genentech, Inc. | $118,638 | Research payment | Cash or cash equivalent | 2023 | ||
| 2023-06-21 | PFIZER INC. | $378 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-06-20 | PFIZER INC. | $4,650 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2023 |
| 2023-06-16 | PFIZER INC. | $1,500 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2023 |
| 2023-06-15 | PFIZER INC. | $1,135 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2023 |
| 2023-06-15 | PFIZER INC. | $756 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-06-15 | PFIZER INC. | $378 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2023 |
| 2023-06-14 | PFIZER INC. | $24,700 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2023 |
| 2023-06-13 | Genentech, Inc. | $16,100 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III OPEN LABEL RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB IN COMB | 2023 |
| 2023-06-13 | PFIZER INC. | $2,268 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-06-07 | PFIZER INC. | $18,500 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2023 |
| 2023-06-07 | PFIZER INC. | $12,601 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2023 |
| 2023-06-06 | PFIZER INC. | $757 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2023 |
| 2023-06-03 | PFIZER INC. | $14,337 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-06-03 | PFIZER INC. | $520 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2023 |
| 2023-06-02 | PFIZER INC. | $1,890 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-06-01 | Genentech, Inc. | $724,800 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2023 |
| 2023-06-01 | PFIZER INC. | $16,815 | Research payment | Cash or cash equivalent | LITFULO Drug, IMMUNOLOGY | A PHASE 3 OPENLABEL MULTICENTER LONGTERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF06651600 IN ADULT AND ADOLESCE | 2023 |
| 2023-05-26 | PFIZER INC. | $33,072 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2023 |
| 2023-05-26 | PFIZER INC. | $22,048 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2023 |
| 2023-05-26 | PFIZER INC. | $16,536 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2023 |
| 2023-05-26 | PFIZER INC. | $5,204 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT | 2023 |
| 2023-05-25 | PFIZER INC. | $66,484 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2023 |
| 2023-05-25 | PFIZER INC. | $4,779 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-05-25 | PFIZER INC. | $3,900 | Research payment | Cash or cash equivalent | A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG | 2023 | |
| 2023-05-24 | PFIZER INC. | $54,929 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2023 |
| 2023-05-24 | PFIZER INC. | $8,329 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-05-24 | PFIZER INC. | $2,605 | Research payment | Cash or cash equivalent | LITFULO Drug, IMMUNOLOGY | A PHASE 3 OPENLABEL MULTICENTER LONGTERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF06651600 IN ADULT AND ADOLESCE | 2023 |
| 2023-05-23 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2023 |
| 2023-05-18 | Genentech, Inc. | $12,000 | Research payment | Cash or cash equivalent | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | 2023 | |
| 2023-05-18 | PFIZER INC. | $5,414 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2023 |
| 2023-05-18 | Genentech, Inc. | $3,500 | Research payment | Cash or cash equivalent | Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC | 2023 | |
| 2023-05-13 | PFIZER INC. | $637 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2023 |
| 2023-05-12 | PFIZER INC. | $9,750 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT | 2023 |
| 2023-05-09 | PFIZER INC. | $7,318 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-05-01 | Genentech, Inc. | $1,043 | Research payment | Cash or cash equivalent | PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC | 2023 | |
| 2023-04-29 | PFIZER INC. | $11,414 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2023 |
| 2023-04-29 | PFIZER INC. | $5,000 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT | 2023 |
| 2023-04-28 | PFIZER INC. | $2,328 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY O | 2023 |
| 2023-04-26 | PFIZER INC. | $10,972 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2023 |
| 2023-04-26 | PFIZER INC. | $3,822 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2023 |
| 2023-04-25 | Genentech, Inc. | $8,651 | Research payment | Cash or cash equivalent | A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC | 2023 | |
| 2023-04-25 | Genentech, Inc. | $1,073 | Research payment | Cash or cash equivalent | CellCept Drug, Virology & Specialty Care | Randomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN | 2023 |
| 2023-04-25 | Genentech, Inc. | $524 | Research payment | Cash or cash equivalent | A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC | 2023 | |
| 2023-04-20 | PFIZER INC. | $6,277 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY O | 2023 |
| 2023-04-19 | PFIZER INC. | $1,251 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2023 |
| 2023-04-12 | PFIZER INC. | $17,000 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2023 |
| 2023-04-04 | PFIZER INC. | $4,500 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-04-01 | PFIZER INC. | $36,865 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY O | 2023 |
| 2023-03-30 | Genentech, Inc. | $1,240 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | Chemo trastuzumab vs chemo trastuzumab pertuzumab | 2023 |
| 2023-03-30 | Genentech, Inc. | $582 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | Chemo trastuzumab vs chemo trastuzumab pertuzumab | 2023 |
| 2023-03-30 | Genentech, Inc. | $582 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | Chemo trastuzumab vs chemo trastuzumab pertuzumab | 2023 |
| 2023-03-30 | Genentech, Inc. | $582 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | Chemo trastuzumab vs chemo trastuzumab pertuzumab | 2023 |
| 2023-03-30 | Genentech, Inc. | $150 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | Chemo trastuzumab vs chemo trastuzumab pertuzumab | 2023 |
| 2023-03-30 | Genentech, Inc. | $75 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | Chemo trastuzumab vs chemo trastuzumab pertuzumab | 2023 |
| 2023-03-29 | PFIZER INC. | $2,000 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2023 |
| 2023-03-28 | PFIZER INC. | $11,924 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2023 |
| 2023-03-23 | Genentech, Inc. | $11,918 | Research payment | Cash or cash equivalent | CellCept Drug, Virology & Specialty Care | Randomised Double blind study to evaluate safety and efficacy of Obinutuzumab in Class III and IV LN | 2023 |
| 2023-03-23 | PFIZER INC. | $9,928 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESIST | 2023 |
| 2023-03-23 | PFIZER INC. | $8,051 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2023 |
| 2023-03-22 | PFIZER INC. | $1,979 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2023 |
| 2023-03-22 | PFIZER INC. | $1,600 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2023 |
| 2023-03-21 | PFIZER INC. | $10,216 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY O | 2023 |
| 2023-03-14 | Genentech, Inc. | $3,099 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2023 | |
| 2023-03-11 | PFIZER INC. | $13,015 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2023 |
| 2023-03-11 | PFIZER INC. | $7,658 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2023 |
| 2023-03-10 | PFIZER INC. | $5,108 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY O | 2023 |
| 2023-03-10 | PFIZER INC. | $4,765 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2023 |
| 2023-03-08 | PFIZER INC. | $364 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-03-02 | Genentech, Inc. | $20,126 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2023 | |
| 2023-03-02 | Genentech, Inc. | $12,000 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2023 | |
| 2023-03-02 | Genentech, Inc. | $4,000 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2023 | |
| 2023-03-02 | Genentech, Inc. | $2,000 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2023 | |
| 2023-03-02 | Genentech, Inc. | $1,875 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2023 | |
| 2023-03-02 | Genentech, Inc. | $1,675 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2023 | |
| 2023-03-02 | PFIZER INC. | $378 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2023 |
| 2023-02-27 | PFIZER INC. | $369,170 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | DESCRIBE CLINICAL CHARACTERISTICS TREATMENT PATTERNS AND INCIDENCE OF DISEASE RECURRENCE AMONG FEMALE PATIENTS DIAGNOSED | 2023 |
| 2023-02-25 | PFIZER INC. | $12,028 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-02-21 | Genentech, Inc. | $72,670 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2023 | |
| 2023-02-21 | Genentech, Inc. | $1,250 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2023 | |
| 2023-02-21 | Genentech, Inc. | $750 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2023 | |
| 2023-02-21 | Genentech, Inc. | $614 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2023 | |
| 2023-02-14 | PFIZER INC. | $36,506 | Research payment | Cash or cash equivalent | ABRYSVO Biological, VACCINES | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2023 |
| 2023-02-14 | PFIZER INC. | $7,202 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY O | 2023 |
| 2023-02-14 | PFIZER INC. | $2,627 | Research payment | Cash or cash equivalent | LITFULO Drug, IMMUNOLOGY | A PHASE 3 OPENLABEL MULTICENTER LONGTERM STUDY INVESTIGATING THE SAFETY AND EFFICACY OF PF06651600 IN ADULT AND ADOLESCE | 2023 |
| 2023-02-04 | PFIZER INC. | $1,620 | Research payment | Cash or cash equivalent | A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED | 2023 | |
| 2023-02-03 | PFIZER INC. | $4,926 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATIONRESIST | 2023 |
| 2023-02-03 | PFIZER INC. | $757 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2023 |
| 2023-02-03 | PFIZER INC. | $378 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2023 |
| 2023-02-02 | Genentech, Inc. | $80,000 | Research payment | Cash or cash equivalent | 2023 | ||
| 2023-02-02 | Genentech, Inc. | $80,000 | Research payment | Cash or cash equivalent | 2023 | ||
| 2023-02-02 | Genentech, Inc. | $38,360 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2023 | |
| 2023-02-02 | Genentech, Inc. | $6,659 | Research payment | Cash or cash equivalent | MyTACTIC Targeting Actionable Mutation Study in Cancer US PIIa multicenter nonrandomized open LBL | 2023 | |
| 2023-01-31 | PFIZER INC. | $16,352 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY O | 2023 |
| 2023-01-28 | PFIZER INC. | $378 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OB | 2023 |
| 2023-01-27 | Genentech, Inc. | $5,133 | Research payment | Cash or cash equivalent | A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC | 2023 |
The latest 200 records of 215.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Antioch, CA, county Contra Costa County, CA, state California; placed by its city name.
| Measure | Place (city or town) Antioch, CA | County Contra Costa County, CA | State California |
|---|---|---|---|
| Population B01003 | 116,477 | 1,165,012 | 39,287,377 |
| Population, 2020 census P1 | 115,291 | 1,165,927 | 39,538,223 |
| Median age B01002 | 38.4 | 40.5 | 37.9 |
| Under 18 B01001 | 22.8% | 22.0% | 22.0% |
| 65 and over B01001 | 14.3% | 17.1% | 15.7% |
| Households B11001 | 37,381 | 414,417 | 13,548,091 |
| Foreign born B05002 | 24.6% | 26.6% | 27.0% |
| Median household income B19013 | $97,465 | $127,229 | $99,122 |
| Median family income B19113 | $109,115 | $148,679 | $113,346 |
| Per capita income B19301 | $41,008 | $62,927 | $49,513 |
| Poverty rate B17001 | 11.4% | 8.4% | 12.0% |
| Unemployment rate B23025 | 7.4% | 6.5% | 6.6% |
| Civilian labor force B23025 | 60,709 | 608,620 | 20,068,466 |
| Mean commute (minutes) B08013 | 42.0 | 35.3 | 28.7 |
| Bachelor's degree or higher B15003 | 23.9% | 45.2% | 37.1% |
| Housing units B25001 | 38,629 | 429,260 | 14,644,735 |
| Owner-occupied B25003 | 63.6% | 68.0% | 55.9% |
| Renters B25003 | 36.4% | 32.0% | 44.1% |
| Median home value B25077 | $629,700 | $866,800 | $734,700 |
| Median gross rent B25064 | $2,278 | $2,375 | $2,036 |
| White, not Hispanic B03002 | 23.4% | 38.1% | 33.8% |
| Black B03002 | 18.2% | 7.9% | 5.2% |
| Hispanic or Latino B03002 | 35.6% | 27.6% | 40.2% |
| Asian B03002 | 13.9% | 18.6% | 15.3% |
| American Indian and Alaska Native B03002 | 0.5% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Antioch, CA.
Comments